Nuvation Bio Inc (NUVB)

Apr 22, 2025, 4:05 PM EDT - 1 day ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 2, 2025, 8:00 AM EDT - 21 days ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Mar 25, 2025, 4:45 PM EDT - 4 weeks ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 8:00 AM EDT - 4 weeks ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 6, 2025, 4:30 PM EST - 6 weeks ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:35 AM EST - 7 weeks ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Feb 24, 2025, 8:00 AM EST - 2 months ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 1:49 PM EST - 2 months ago

Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm

Feb 13, 2025, 5:09 PM EST - 2 months ago

Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst

Feb 3, 2025, 8:00 AM EST - 2 months ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 4:05 PM EST - 3 months ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:00 AM EST - 3 months ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 2, 2025, 7:00 PM EST - 3 months ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Dec 23, 2024, 8:00 AM EST - 4 months ago

U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer

Dec 20, 2024, 7:10 AM EST - 4 months ago

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Nov 26, 2024, 8:00 AM EST - 5 months ago

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 4:05 PM EST - 5 months ago

Nuvation Bio to Present at the Jefferies London Healthcare Conference

Nov 11, 2024, 6:18 AM EST - 5 months ago

Top 4 Health Care Stocks That May Plunge This Quarter

AIRS PODD QDEL

Nov 6, 2024, 4:05 PM EST - 6 months ago

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 7, 2024, 4:05 PM EDT - 7 months ago

Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

Sep 14, 2024, 3:05 AM EDT - 7 months ago

Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024

Sep 9, 2024, 8:00 AM EDT - 8 months ago

Nuvation Bio to Present at the Cantor Global Healthcare Conference

Aug 8, 2024, 3:51 PM EDT - 9 months ago

Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024

Aug 5, 2024, 8:00 AM EDT - 9 months ago

Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 23, 2024, 4:05 PM EDT - 9 months ago

Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib

Jun 2, 2024, 1:13 AM EDT - 11 months ago

Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting

Jun 1, 2024, 8:00 PM EDT - 11 months ago

Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

Jun 1, 2024, 8:10 AM EDT - 11 months ago

Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting

May 29, 2024, 4:05 PM EDT - 11 months ago

Nuvation Bio to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:01 AM EDT - 1 year ago

Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 10, 2024, 4:01 PM EDT - 1 year ago

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

Mar 31, 2024, 10:00 AM EDT - 1 year ago

Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Mar 14, 2024, 4:05 PM EDT - 1 year ago

Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors

Feb 29, 2024, 4:01 PM EST - 1 year ago

Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Jan 8, 2024, 4:10 PM EST - 1 year ago

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Jan 8, 2024, 4:05 PM EST - 1 year ago

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nov 13, 2023, 4:05 PM EST - 1 year ago

Nuvation Bio Announces Departure of Chief Financial Officer

Nov 2, 2023, 4:10 PM EDT - 1 year ago

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 3, 2023, 4:47 AM EDT - 1 year ago

Nuvation: Cash Is King, Science Is An Afterthought

Aug 3, 2023, 4:10 PM EDT - 1 year ago

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 4:05 PM EDT - 2 years ago

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

May 4, 2023, 4:05 PM EDT - 2 years ago

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Mar 15, 2023, 4:05 PM EDT - 2 years ago

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Dec 19, 2022, 4:05 PM EST - 2 years ago

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

Nov 3, 2022, 4:05 PM EDT - 2 years ago

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

Aug 4, 2022, 4:05 PM EDT - 2 years ago

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 1, 2022, 8:00 AM EDT - 2 years ago

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program